بدائل البحث:
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
gap decrease » gain decreased (توسيع البحث), step decrease (توسيع البحث), _ decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
gap decrease » gain decreased (توسيع البحث), step decrease (توسيع البحث), _ decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
-
7521
The flow chart of the study.
منشور في 2025"…Hematocrit in the first 2 hours of life, considered as a continuous variable, was significantly associated with short-term outcomes in univariate analyses (P < 0.05). …"
-
7522
Baseline characteristics of participants.
منشور في 2025"…Hematocrit in the first 2 hours of life, considered as a continuous variable, was significantly associated with short-term outcomes in univariate analyses (P < 0.05). …"
-
7523
Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i>
منشور في 2024"…In this regard, bioderived nanovesicles have shown significant promise. This work demonstrated significant antibacterial properties of extracellular nanovesicles derived from plant (mint) leaf juice (MENV). …"
-
7524
Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i>
منشور في 2024"…In this regard, bioderived nanovesicles have shown significant promise. This work demonstrated significant antibacterial properties of extracellular nanovesicles derived from plant (mint) leaf juice (MENV). …"
-
7525
-
7526
pHI for net status.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7527
Combined net integrity PBO and LLINs-PLOS1.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7528
Factors affecting pyrethroid-LLINs integrity.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7529
Factors associated with mosquito net integrity.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7530
LLINs knockdown performance over time.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7531
Factors affecting PBO-LLINs integrity.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7532
Net bioefficacy data.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7533
House structure and status.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7534
LLINs hole positions over time.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7535
-
7536
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7537
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7538
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7539
Table 3_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx
منشور في 2025"…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …"
-
7540
Table 1_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx
منشور في 2025"…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …"